Diabetes Draft Guidance May Require Extended Trial Length, Participation
Executive Summary
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
You may also be interested in...
Type 2 Diabetes Drugs Can Skip Cardiovascular Outcome Trials, But Phase III Must Be Longer, Broader
US FDA withdraws controversial 2008 guidance that required sponsors to exclude threshold levels of cardiovascular risk before and after approval; new draft guidelines emphasize duration of exposure and breadth of safety evaluations in more diverse Phase III trial population, consistent with advisory committee recommendations.
FDA Plans To Add Specifics To Statistical Part Of Antidiabetics CV Guidance
FDA expects to make changes to its final guidance on evaluating cardiovascular risk for new type 2 diabetes drugs based on the experience gained from sponsors' implementation of the guidance
FDA Plans To Add Specifics To Statistical Part Of Antidiabetics CV Guidance
FDA expects to make changes to its final guidance on evaluating cardiovascular risk for new type 2 diabetes drugs based on the experience gained from sponsors' implementation of the guidance